Ad is loading...
MENU

ALNY Stock Alnylam Pharmaceuticals (ALNY, $268.95) price exceeded its 50-day Moving Average on November 12, 2024

A.I.dvisor
at Tickeron.com
Loading...
ALNY - Alnylam Pharmaceuticals
Moving Avg. signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Moving Avg. signal
Price: $268.95
Daily change: -$10.87 (-3.88%)
Daily volume: 1M
Capitalization: $34.7B
Industry: Biotechnology
This price move could indicate a change in the trend, and may be a sell signal for investors. A.I.dvisor found 47 similar cases, and were successful. Based on this data, the odds of success are

ALNY sees MACD Histogram just turned negative

ALNY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 28, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ALNY moved below its 50-day moving average on November 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on November 11, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALNY entered a downward trend on November 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Oscillator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALNY's P/B Ratio (1000.000) is very high in comparison to the industry average of (13.752). P/E Ratio (0.000) is within average values for comparable stocks, (88.017). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.790). ALNY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (15.060) is also within normal values, averaging (224.437).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ALNY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics based on RNA interference

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
675 West Kendall Street
Phone
+1 617 551-8200
Employees
2100
Web
https://www.alnylam.com